Sermorelin Acetate – Injection

Sermorelin Injection is a compounded, synthetic 29-amino acid analog of growth hormone-releasing hormone (GHRH), primarily indicated for diagnostic testing and treatment of pediatric and adult growth hormone deficiency, and studied for investigational use in age-related GH decline, muscle wasting, and anti-aging protocols.

Sermorelin acts as a GHRH analog, binding to pituitary receptors to trigger natural, pulsatile secretion of endogenous GH, suppress somatostatin inhibition, and upregulate GH gene transcription. Elevated GH is associated with increased IGF-1, with downstream effects on growth, body composition, and metabolism. This physiologic feedback system reduces the risk of overdose and excessive GH exposure.

Sermorelin has a favorable safety profile. Adverse effects are typically mild and transient, including injection site pain, redness, swelling, transient flushing, headache, dizziness, and less commonly urticaria, somnolence, or hyperactivity. Severe hypersensitivity is rare, with minimal long-term risks and no documented cases of addiction or systemic toxicity.

Contraindications: Hypersensitivity to sermorelin or excipients; Pregnancy/lactation; no safety data.
Precautions: Use caution in patients with diabetes, pituitary disorders, or concurrent hormone therapies; compounding restricted to certified pharmacies by prescription.